All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged new theophine GLP-1 receptor agonists reported to be useful for the treatment of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, obesity, glucose intolerance, dyslipidemia, hyperinsulinemia and insulin resistance.
